Adjuvant Capital — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

LimmaTech Biologicslmtbio.com inSeries A · Feb 2024 · $36Macquired by Lilly

LimmaTech develops vaccine technologies and programs designed to combat antimicrobial-resistant pathogens and prevent severe infections.

AI & Machine LearningBiotechHealthtechMedical Devices

Co-investorsAndera Partners Novo Holdings Tenmile

Memo Therapeutics AGmemo-therapeutics.com inSeries B · May 2024 · $25Macquired by Clementia

Memo Therapeutics develops therapeutic antibodies targeting viral infections to improve treatment outcomes for patients with conditions like BKPyV infection in kidney transplant recipients and oncological viral diseases.

BiotechMedical DevicesZurich, CH

Co-investorsKurma Partners Pureos Bioventures Ysios Capital Fresenius Medical Care Ventures Verve Ventures redalpine

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.